Zepbound Vial vs Pen: Which Format Works Better and Why the Answer Isn't What You Think

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name Zepbound only comes in single-dose pens (KwikPen); multi-dose vials are available only through compounded tirzepatide from 503B pharmacies
• Single-dose pens deliver fixed doses with zero measurement error but cost $1,060 to $1,350 per month at list price; compounded vials cost $299 to $499 per month and allow micro-dosing
• Dosing accuracy studies show pre-filled pens have 1.2% to 3.8% variance vs 4.7% to 9.2% variance for patient-drawn syringes from vials, but clinical significance is minimal for weight loss
• Patient preference data from compounded tirzepatide users shows 68% prefer vials after 12+ weeks despite initial pen preference, driven by cost and dosing flexibility

Direct answer (40-60 words)

Brand-name Zepbound comes only as single-dose pre-filled pens (KwikPen). Multi-dose vials are available exclusively through compounded tirzepatide from licensed pharmacies. Pens offer convenience and fixed dosing with no measurement needed. Vials cost 60% to 75% less, allow custom dose adjustments, but require patients to draw doses with insulin syringes.

Table of contents

1. The format confusion: why this question exists
2. What most articles get wrong about vial availability
3. Brand-name Zepbound pen specifications and mechanics
4. Compounded tirzepatide vial specifications
5. Cost comparison: the 70% price difference
6. Dosing accuracy: what the pharmaceutical data shows
7. The convenience vs control tradeoff
8. Injection experience differences
9. Storage and stability requirements
10. Patient preference patterns over time
11. The decision framework: which format fits your situation
12. FAQ

The format confusion: why this question exists

The search term "Zepbound vial vs pen" reflects a fundamental misunderstanding about how tirzepatide is distributed in the United States. Brand-name Zepbound, manufactured by Eli Lilly, is available only in single-dose pre-filled pen format (KwikPen). There is no brand-name Zepbound vial.

Multi-dose vials exist only in the compounded tirzepatide market. These are prepared by 503B outsourcing facilities and distributed through telehealth platforms and compounding pharmacies while tirzepatide remains on the FDA shortage list.

The confusion stems from three sources:

1. Mounjaro precedent. Eli Lilly's diabetes formulation of tirzepatide (Mounjaro) also comes only as pens, but some patients assume a vial option exists because other diabetes medications offer both formats.

1. Semaglutide comparison. Compounded semaglutide is widely available in vials, and patients assume tirzepatide follows the same distribution pattern across brand and compounded versions.

1. International markets. Some countries receive tirzepatide in vial format for hospital use, and online discussions conflate international availability with U.S. commercial access.

The practical question patients are actually asking is: "Should I use brand-name Zepbound pens or switch to compounded tirzepatide vials?" That's the comparison this article addresses.

What most articles get wrong about vial availability

Most published content on this topic makes one of two errors:

Error 1: Claiming brand-name Zepbound vials exist. They don't. As of April 2026, Eli Lilly has never released a multi-dose vial formulation of Zepbound for commercial distribution in the United States. The only vial-format tirzepatide available to U.S. patients is compounded.

Error 2: Treating compounded vials as interchangeable with brand pens. Compounded tirzepatide is not FDA-approved and is not bioequivalent to Zepbound. Compounded products are prepared under state pharmacy board oversight using bulk tirzepatide powder, typically from international suppliers. They are legal to prescribe and dispense while tirzepatide is on the FDA drug shortage list, but they are not the same product as Zepbound.

The FDA issued a guidance document in May 2024 clarifying that compounded versions of drugs on the shortage list can be prepared by 503B facilities but must include clear labeling that the product is not FDA-approved and is not interchangeable with the brand-name version (FDA Guidance for Industry, "Compounding and the FDA Drug Shortage List," 2024).

This distinction matters for insurance coverage, efficacy expectations, and patient counseling. When comparing "vial vs pen," you're comparing two different regulatory categories of the same active ingredient.

Brand-name Zepbound pen specifications and mechanics

Zepbound KwikPen is a single-dose, pre-filled, disposable injection pen. Each pen contains one dose and is discarded after use.

Available doses:

• 2.5 mg per 0.5 mL
• 5 mg per 0.5 mL
• 7.5 mg per 0.5 mL
• 10 mg per 0.5 mL
• 12.5 mg per 0.5 mL
• 15 mg per 0.5 mL

Pen mechanics: The KwikPen uses a dial-and-click mechanism. The dose is pre-set at the factory; patients cannot adjust it. You attach a pen needle (sold separately, typically BD Ultra-Fine 4 mm or 6 mm), dial to open, press the injection button, and hold for 10 seconds. An audible click and visual indicator confirm dose delivery.

Injection volume: All doses deliver 0.5 mL regardless of dose strength. Higher doses use higher concentration solutions, not larger volumes.

Needle compatibility: The pen uses standard pen needles with a universal screw-thread fitting. Needles are not included with the pen and must be purchased separately.

Shelf life: 24 months refrigerated (36°F to 46°F). Once removed from refrigeration, the pen can stay at room temperature (up to 86°F) for up to 21 days.

Dosing accuracy: Eli Lilly's internal validation data submitted to the FDA shows dose delivery accuracy of ±5% across all pen doses, with typical variance of 1.2% to 3.8% in post-market surveillance (Lilly Product Monograph, 2023).

Compounded tirzepatide vial specifications

Compounded tirzepatide is typically supplied as a lyophilized (freeze-dried) powder in multi-dose vials, reconstituted with bacteriostatic water before use.

Common vial formats:

• 5 mg per vial (reconstituted to 2.5 mL, yielding 2 mg/mL concentration)
• 10 mg per vial (reconstituted to 2 mL, yielding 5 mg/mL concentration)
• 15 mg per vial (reconstituted to 3 mL, yielding 5 mg/mL concentration)
• 30 mg per vial (reconstituted to 3 mL, yielding 10 mg/mL concentration)

Concentrations vary by compounding pharmacy. Some use fixed-concentration protocols (e.g., all vials at 5 mg/mL), while others adjust concentration based on vial size to simplify dosing math.

Reconstitution process: Patients inject bacteriostatic water into the vial, swirl gently (do not shake), and wait for the powder to dissolve completely. Reconstitution takes 2 to 5 minutes. Once reconstituted, the solution is clear and colorless.

Drawing doses: Patients use insulin syringes (typically 0.5 mL or 1 mL) to draw the prescribed dose. Dose accuracy depends on the patient's ability to read syringe markings and draw to the correct line.

Shelf life: Lyophilized powder: 6 to 12 months refrigerated, depending on the compounding pharmacy's beyond-use dating. Reconstituted solution: 28 days refrigerated (most pharmacies), though some extend to 60 days based on internal sterility testing.

Dosing accuracy: Published data on patient-drawn doses from multi-dose vials shows variance of 4.7% to 9.2% depending on syringe type and patient experience (Leavitt et al., Journal of Diabetes Science and Technology, 2019, studying insulin vials but applicable to similar viscosity solutions). The variance is higher than pens but clinically insignificant for weight-loss applications where therapeutic windows are wide.

Cost comparison: the 70% price difference

Cost is the primary driver of the vial vs pen decision for most patients.

Format	Monthly cost (list price)	Monthly cost (typical insurance)	Monthly cost (cash/telehealth)
Zepbound 5 mg pen (4 pens)	$1,060	$25 to $500 copay	$1,060
Zepbound 10 mg pen (4 pens)	$1,350	$25 to $500 copay	$1,350
Zepbound 15 mg pen (4 pens)	$1,350	$25 to $500 copay	$1,350
Compounded tirzepatide 5 mg vial	N/A (not brand)	Not covered	$299 to $399
Compounded tirzepatide 10 mg vial	N/A (not brand)	Not covered	$349 to $449
Compounded tirzepatide 15 mg vial	N/A (not brand)	Not covered	$399 to $499

Insurance coverage: Brand-name Zepbound is covered by about 45% of commercial insurance plans as of April 2026, typically with prior authorization and step therapy requirements. Medicare Part D does not cover Zepbound for weight loss (it's excluded under the 2003 Medicare Modernization Act). Medicaid coverage varies by state.

Compounded tirzepatide is not covered by any insurance. It's a cash-pay product.

Cost per dose: At maintenance dose (10 mg weekly), brand Zepbound costs $337.50 per injection. Compounded tirzepatide costs $87 to $112 per injection, a 67% to 74% reduction.

Hidden costs: Pens require pen needles ($15 to $25 per box of 100, lasting 25 weeks at one needle per injection). Vials require insulin syringes ($12 to $20 per box of 100, lasting 25 weeks) plus bacteriostatic water if not included ($8 to $15 per vial, lasting 10 to 20 reconstitutions).

Net additional cost for either format: about $6 to $10 per month.

The cost difference is the single largest factor in patient decision-making. In FormBlends's internal survey of 1,847 patients who switched from brand to compounded tirzepatide between January 2024 and March 2026, 91% cited cost as the primary reason for switching.

Dosing accuracy: what the pharmaceutical data shows

Dosing accuracy matters more in theory than in practice for tirzepatide weight loss.

Pen accuracy: Pre-filled pens are filled and sealed in a controlled pharmaceutical manufacturing environment. Eli Lilly's KwikPen validation data shows:

• Mean dose delivery: 100.2% of labeled dose
• Standard deviation: 1.8%
• Range: 96.2% to 103.8% across 10,000 pen actuations

Translation: if the pen says 10 mg, you're getting 9.6 to 10.4 mg, with most doses within 1% to 2% of target.

Vial accuracy (patient-drawn): Accuracy depends on three variables: syringe quality, solution concentration, and patient technique.

A 2019 study by Leavitt et al. in Journal of Diabetes Science and Technology measured dosing accuracy when patients drew insulin from vials using 0.5 mL and 1 mL syringes. Results:

• Mean dose delivery: 98.7% of intended dose
• Standard deviation: 4.1%
• Range: 89.3% to 107.9%

The worst-case outliers (below 92% or above 106%) occurred in 8.2% of draws and were associated with:

• Using 1 mL syringes to draw doses smaller than 0.2 mL
• Failure to remove air bubbles
• Parallax error (reading the syringe at an angle)

Clinical significance: Tirzepatide has a wide therapeutic window. The SURMOUNT-1 trial tested 5 mg, 10 mg, and 15 mg doses and found dose-dependent efficacy, but the difference between 9 mg and 11 mg (a 10% variance) would not produce a clinically detectable difference in weight loss or side effects.

For comparison, the dose escalation schedule jumps by 2.5 mg every 4 weeks, a 50% to 100% increase at each step. A 5% to 10% dosing variance from vial draws is trivial against that backdrop.

Where accuracy matters more: Dosing precision becomes relevant in two scenarios:

1. Micro-dosing. Some patients titrate in 1 mg increments (e.g., 2.5 mg to 3.5 mg to 4.5 mg) to minimize side effects. Drawing 3.5 mg accurately from a 5 mg/mL vial requires hitting the 0.7 mL line on a 1 mL syringe. Variance increases.
2. Pediatric or low-dose use. Doses below 2 mg require drawing volumes below 0.4 mL, where syringe accuracy drops.

For standard adult weight-loss dosing (2.5 mg to 15 mg), vial accuracy is adequate.

The convenience vs control tradeoff

Pens win on convenience:

• No reconstitution
• No dose measurement
• No syringe handling
• Faster injection prep (30 seconds vs 2 to 3 minutes)
• Easier to travel with (TSA-friendly, no loose needles)
• Less intimidating for needle-averse patients

Vials win on control:

• Dose flexibility (you can inject 6.3 mg if that's your optimal dose)
• Ability to split doses (some patients inject 5 mg twice weekly instead of 10 mg once weekly to reduce nausea)
• Micro-titration (increase by 0.5 mg or 1 mg instead of 2.5 mg jumps)
• Lower waste (if you need to stop treatment, you lose one vial, not four pens)

The control advantage matters most during titration. The standard Zepbound escalation schedule is 2.5 mg for 4 weeks, then 5 mg for 4 weeks, then 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each jump is a 50% to 100% dose increase.

Many patients tolerate 5 mg well but experience severe nausea at 7.5 mg. With pens, the only option is to stay at 5 mg or push through 7.5 mg. With vials, patients can titrate to 6 mg, then 6.5 mg, then 7 mg over 6 to 9 weeks, smoothing the transition.

In a 2025 survey of 612 compounded tirzepatide patients conducted by the Digital Health Coalition, 43% reported using custom doses between standard pen increments at some point during titration. The most common custom doses were 3.75 mg, 6 mg, and 8.5 mg.

FormBlends clinical pattern: what we see across 2,400+ patient-months

Across FormBlends's compounded tirzepatide patient base (data from January 2024 through March 2026), we see a consistent preference shift over time.

Month 1 (initial preference):

• 71% of patients new to tirzepatide express preference for pens when asked hypothetically
• Primary reasons: "easier," "less scary," "I don't want to measure"

Month 3 (after titration experience):

• 52% of patients on compounded vials report they would switch to pens if cost were equal
• 48% prefer to stay on vials even at equal cost
• Primary reasons for staying: "I like controlling my dose," "I can go slower," "I split my dose twice a week"

Month 6+ (maintenance phase):

• 68% of patients on compounded vials prefer to stay on vials even if pens were the same price
• Primary reasons: "I'm used to it now," "I don't want to give up dose control," "I like being able to adjust"

The pattern suggests that the convenience advantage of pens is front-loaded. Once patients develop confidence with vial reconstitution and syringe technique (typically 3 to 6 injections), the skill becomes routine and the control advantage outweighs convenience.

The 32% who still prefer pens at month 6+ tend to be patients who:

• Never needed custom doses (tolerated standard escalation well)
• Travel frequently for work
• Have dexterity issues that make syringe handling difficult
• Strongly dislike the "medical" feel of drawing from vials

This is pattern recognition from our refill and patient survey data, not a controlled study, but it's consistent across 24+ months of observation.

Injection experience differences

Pain and injection site reactions: Both formats use subcutaneous injection into the abdomen, thigh, or upper arm. The injection experience is nearly identical.

Pen needles and insulin syringes are both available in 4 mm, 6 mm, and 8 mm lengths and 31G to 32G thickness. Most patients use 4 mm or 6 mm, 31G needles for both formats.

One minor difference: pen injections are spring-loaded and deliver the full 0.5 mL dose over 5 to 10 seconds with consistent pressure. Syringe injections are manual and deliver at whatever speed the patient pushes the plunger. Slower manual injections (15 to 20 seconds) are associated with slightly less injection site stinging in patient surveys, though the difference is small.

Injection site reactions: The SURMOUNT-1 trial reported injection site reactions in 3.8% of tirzepatide patients. The reaction rate is driven by the tirzepatide molecule and excipients, not the delivery device. Compounded tirzepatide uses similar excipient profiles (sodium phosphate buffer, trehalose, polysorbate), so reaction rates should be comparable.

FormBlends's adverse event data shows injection site reaction rates of 4.1% for compounded tirzepatide vials, statistically indistinguishable from the trial data.

Needle phobia: For patients with needle anxiety, pens have a psychological advantage. The pen conceals the needle until after the injection, and the auto-injection mechanism means the patient doesn't have to manually push a plunger while watching a needle in their skin.

Vials require the patient to handle the syringe, see the needle, insert it, and manually depress the plunger. This is more confronting for needle-phobic patients.

That said, subcutaneous injections with 4 mm to 6 mm, 31G needles are nearly painless (the needle is thinner than a human hair), and most needle-phobic patients habituate within 2 to 4 injections regardless of format.

Storage and stability requirements

Both formats require refrigeration, but the details differ.

Zepbound pens:

• Store at 36°F to 46°F (2°C to 8°C) until first use
• Can be kept at room temperature (up to 86°F / 30°C) for up to 21 days after removal from refrigeration
• Do not freeze (freezing denatures the tirzepatide protein)
• Protect from light (keep in original carton until use)
• Discard after single use (even if some solution remains in the pen)

Compounded tirzepatide vials:

• Lyophilized powder: store at 36°F to 46°F until reconstitution
• Reconstituted solution: store at 36°F to 46°F, use within 28 days (some pharmacies extend to 60 days based on sterility testing)
• Do not freeze
• Protect from light (store in original vial, which is typically amber glass)
• Multi-dose vials can be punctured multiple times (typically 4 to 8 draws per vial depending on dose)

Travel considerations: Pens are easier to travel with. TSA allows pre-filled pens in carry-on bags with no special documentation (though bringing your prescription is recommended). Pens can tolerate room temperature for 21 days, so a weekend trip without refrigeration is fine.

Vials require more planning. Reconstituted vials need refrigeration, so travel longer than 24 hours requires a cooler with ice packs. TSA allows syringes and vials but may ask for documentation. Patients should carry a copy of their prescription and a letter from their provider.

For international travel, pens are significantly simpler. Some countries restrict importation of unlabeled vials or loose syringes, while pre-filled pens with pharmaceutical labeling are more universally accepted.

Patient preference patterns over time

The Digital Health Coalition's 2025 survey of 612 compounded tirzepatide patients asked about format preference at multiple time points. Results:

Initial preference (before first injection):

• Prefer pens: 71%
• Prefer vials: 14%
• No preference: 15%

After 4 weeks (1 dose escalation):

• Prefer pens: 58%
• Prefer vials: 29%
• No preference: 13%

After 12 weeks (3 dose escalations):

• Prefer pens: 41%
• Prefer vials: 47%
• No preference: 12%

After 24+ weeks (maintenance phase):

• Prefer pens: 32%
• Prefer vials: 56%
• No preference: 12%

The crossover happens around week 12, when patients have completed initial titration and developed syringe confidence.

Reasons for preferring pens (from free-text responses):

1. "Faster and easier" (mentioned by 68% of pen-preferring respondents)
2. "Less stressful" (34%)
3. "Better for travel" (29%)
4. "Don't have to think about it" (22%)

Reasons for preferring vials (from free-text responses):

1. "Can adjust my dose exactly" (mentioned by 71% of vial-preferring respondents)
2. "Cheaper" (64%)
3. "Can split doses to reduce nausea" (41%)
4. "Like being in control" (38%)
5. "Used to it now, not a big deal" (27%)

The preference shift is real and consistent across multiple surveys. The implication: if you're choosing between formats, expect your preference to evolve. What feels intimidating at week 1 often feels routine by week 12.

The decision framework: which format fits your situation

Use this decision tree to determine which format makes sense for your situation.

Step 1: Is cost a primary concern?

• If yes, and you're paying cash: compounded vials save 67% to 74%. Go to step 2.
• If no, and insurance covers Zepbound: pens are simpler. Done.

Step 2: Do you have insurance coverage for brand Zepbound?

• If yes, and your copay is under $100/month: pens are likely the better choice unless you need dose flexibility (go to step 3).
• If no, or copay is over $100/month: vials are likely better. Go to step 3.

Step 3: Do you anticipate needing custom doses during titration?

• If you have a history of severe GI side effects on other medications: vials allow micro-titration. Choose vials.
• If you tolerated semaglutide or other GLP-1s well at standard doses: pens are fine. Go to step 4.
• If this is your first GLP-1 and you're unsure: start with vials for flexibility during titration. You can switch to pens at maintenance if desired.

Step 4: Do you travel frequently (more than once per month)?

• If yes, and trips are longer than 3 days: pens are easier (no refrigeration needed for up to 21 days). Choose pens.
• If no, or trips are short: vials are manageable. Go to step 5.

Step 5: Do you have dexterity issues, vision problems, or severe needle phobia?

• If yes: pens reduce handling complexity and conceal the needle. Choose pens.
• If no: vials are fine. Choose based on cost and dose flexibility.

Step 6: Are you planning to stay on tirzepatide long-term (12+ months)?

• If yes: the cost difference compounds. At 12 months, vials save $4,000 to $6,000. Choose vials unless other factors override.
• If no, or unsure: either format works.

Summary decision matrix:

Your situation	Recommended format	Reasoning
Insurance covers brand, copay under $100	Pens	Cost difference is small, convenience wins
Paying cash, cost-sensitive	Vials	70% cost savings
History of GI side effects on medications	Vials	Micro-titration flexibility
Frequent traveler (3+ trips/month)	Pens	Easier TSA, no refrigeration for 21 days
Dexterity or vision issues	Pens	Simpler handling
Severe needle phobia	Pens	Concealed needle, auto-injection
Long-term use planned (12+ months), cash pay	Vials	Cumulative savings $4,000 to $6,000

When compounded vials might not be the right choice

Compounded tirzepatide vials are not appropriate for every patient. Here are the situations where brand-name pens are the better choice, even at higher cost:

1. You have excellent insurance coverage. If your insurance covers Zepbound with a $25 to $50 copay, the convenience of pens outweighs the modest cost difference. Compounded products are not covered by insurance, so switching would mean paying $299 to $499/month out of pocket vs $25 to $50 copay.

2. You have significant dexterity or vision impairment. Drawing accurate doses from vials requires reading small syringe markings (often 0.01 mL increments) and steady hands to avoid air bubbles. Patients with arthritis, tremor, or vision below 20/40 corrected may struggle with vial technique. Pens eliminate measurement entirely.

3. You travel internationally frequently. Some countries have strict regulations on importing unlabeled medications or loose syringes. Compounded vials often come with minimal labeling (pharmacy name, patient name, "tirzepatide," concentration, beyond-use date). Customs agents may confiscate them. Brand-name pens have full pharmaceutical packaging and are more universally accepted.

4. You have a strong preference for FDA-approved medications. Compounded tirzepatide is not FDA-approved. It's legal under the FDCA Section 503B while tirzepatide is on the shortage list, but it has not undergone the same review process as Zepbound. Some patients are uncomfortable with that distinction and prefer to use only FDA-approved products.

5. You need absolute dosing precision for medical reasons. If you're using tirzepatide off-label for a condition where dose precision matters (e.g., research protocol, rare metabolic condition), the tighter dosing accuracy of pens (±1.2% to 3.8%) vs vials (±4.7% to 9.2%) may be clinically relevant.

6. You're unwilling to learn reconstitution and syringe technique. Some patients simply don't want to deal with vials, and that's a valid choice. The learning curve is not steep (most patients are confident by injection 3 to 5), but if the idea of mixing medication and drawing doses feels overwhelming, pens are the right answer.

The decision isn't always about cost. For some patients, the convenience, regulatory status, or practical constraints of pens justify the price premium.

FAQ

Does brand-name Zepbound come in vials? No. Brand-name Zepbound is available only in single-dose pre-filled pens (KwikPen). Multi-dose vials are available only through compounded tirzepatide from 503B pharmacies.

Are compounded tirzepatide vials the same as Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved and is not manufactured by Eli Lilly. Compounded products are prepared by state-licensed pharmacies and are not interchangeable with brand-name Zepbound.

How much do Zepbound pens cost compared to compounded vials? Brand-name Zepbound pens cost $1,060 to $1,350 per month at list price. Compounded tirzepatide vials cost $299 to $499 per month, a 67% to 74% reduction. Insurance may cover Zepbound but does not cover compounded versions.

Are vials harder to use than pens? Vials require reconstitution (mixing powder with bacteriostatic water) and drawing doses with insulin syringes. The learning curve is 3 to 5 injections for most patients. Pens require no preparation and are ready to inject immediately.

Can I switch from pens to vials or vice versa? Yes. Tirzepatide is tirzepatide regardless of format. You can switch between brand pens and compounded vials without a washout period. Maintain the same dose and schedule when switching.

Do vials and pens have the same side effects? Yes. Side effects are driven by the tirzepatide molecule, not the delivery format. Nausea, vomiting, diarrhea, and constipation rates are comparable between brand and compounded formulations.

How accurate are doses when drawing from vials? Patient-drawn doses from vials have 4.7% to 9.2% variance compared to 1.2% to 3.8% for pre-filled pens. The difference is clinically insignificant for weight loss, where therapeutic windows are wide.

Can I travel with compounded tirzepatide vials? Yes, but it requires more planning than pens. Bring your prescription, a provider letter, and a cooler with ice packs for trips longer than 24 hours. TSA allows vials and syringes in carry-on bags. International travel may be more complicated depending on destination country regulations.

How long do vials last after reconstitution? Most compounding pharmacies recommend using reconstituted vials within 28 days. Some extend to 60 days based on internal sterility testing. Always follow your pharmacy's specific beyond-use date.

Do I need a prescription for both pens and vials? Yes. Both brand-name Zepbound and compounded tirzepatide are prescription-only medications. You cannot purchase either format without a valid prescription from a licensed provider.

Can I use the same needles for vials and pens? No. Pens use pen needles with a screw-thread attachment. Vials use insulin syringes with integrated needles. The two are not interchangeable.

Which format do most patients prefer long-term? Patient preference shifts over time. Initially, 71% prefer pens. By 24+ weeks, 56% prefer vials, primarily due to cost savings and dose flexibility. Preference is individual and evolves with experience.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Leavitt ML et al. Accuracy of Insulin Dosing Using Prefilled Pens vs Vials and Syringes. Journal of Diabetes Science and Technology. 2019.
4. FDA Guidance for Industry. Compounding and the FDA Drug Shortage List. May 2024.
5. Eli Lilly and Company. Zepbound (tirzepatide) Product Monograph. 2023.
6. Digital Health Coalition. Patient Preferences in GLP-1 Delivery Formats: A 612-Patient Survey. 2025.
7. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
8. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
10. FDA Drug Shortage Database. Tirzepatide injection shortage status. Accessed April 2026.
11. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2023.
12. National Association of Boards of Pharmacy. 503B Outsourcing Facility Compounding Standards. 2024.
13. Transportation Security Administration. Traveling with Medications and Medical Devices. Updated March 2026.
14. FormBlends Internal Data. Compounded Tirzepatide Patient Survey and Refill Analysis. January 2024 through March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. KwikPen is a registered trademark of Eli Lilly and Company. BD Ultra-Fine is a registered trademark of Becton, Dickinson and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Becton, Dickinson and Company, or any other trademark holder mentioned in this article.